{"id":17672,"date":"2014-02-21T02:30:00","date_gmt":"2014-02-21T01:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/pseudoscienza-miracoli-truffe-e-miti-da-sfatare\/"},"modified":"2014-02-21T02:30:00","modified_gmt":"2014-02-21T01:30:00","slug":"pseudoscienza-miracoli-truffe-e-miti-da-sfatare","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/pseudoscienza-miracoli-truffe-e-miti-da-sfatare\/","title":{"rendered":"Pseudoscience, miracles, scams and myths to debunk"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\"><span style=\"font-family: BookAntiqua; color: #212120; font-size: 12pt; mso-bidi-font-family: BookAntiqua\"><font face=\"Calibri\">Pharmaceutical companies can be sued for paying rival companies to delay the release of low-cost versions of their medicines. This was decided by the American Supreme Court, thus rewriting the rules governing the release of generic drugs on the market. <\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\"><span style=\"font-family: BookAntiqua; color: #212120; font-size: 12pt; mso-bidi-font-family: BookAntiqua\"><font face=\"Calibri\">The ruling is a victory for the Federal Trade Commission and the Obama administration, reversing an earlier decision by junior judges that exempted pharmaceutical companies from this kind of liability. The FTC assures that these types of agreements, renamed &#039;pay for delay&#039;, cost the health system and patients up to 3.5 billion dollars a year. <\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt; text-autospace: ; mso-layout-grid-align: none\"><span style=\"font-family: BookAntiqua; color: #212120; font-size: 12pt; mso-bidi-font-family: BookAntiqua\"><font face=\"Calibri\">While according to the industry these are legitimate patent agreements. In 2012, 40 were signed, again according to estimates by the US Federal Commission.<\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; margin: 0cm 0cm 8pt\"><i><span style=\"line-height: 107%; font-family: &quot;Times New Roman&quot;,&quot;serif&quot;; color: #212120; font-size: 9pt; mso-bidi-font-weight: bold\">Barbara Di Chiara \u2013 19 June 2013 \u2013 PharmaKronos<\/span><\/i><span style=\"line-height: 107%; font-size: 9pt\"><\/p>\n<p><\/span><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: left\">&nbsp; <img","protected":false},"excerpt":{"rendered":"<p>Le aziende farmaceutiche possono essere citate in giudizio per aver pagato imprese rivali allo scopo di ritardare l&#8217;arrivo in commercio di versioni a basso costo dei loro medicinali. Lo ha deciso la Corte Suprema americana, riscrivendo in questo modo le norme che disciplinano il rilascio sul mercato dei farmaci generici. La sentenza &egrave; una vittoria &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-17672","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=17672"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17672\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=17672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=17672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=17672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}